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INTRODUCTION 
Pulsatile system is amongst one of them and gaining a lot 
of interest as it is increasing patient compliance by means 
of providing time- and site-specific drugdelivery system, 
thus providing special Pulsed or pulsatile drug release is 
defined as the rapid and transient release of a certain 
amount of drug molecules within a short time-period 
immediately after a predetermined off-release period1. 
Pulsatile release is commonly found in the body, for 
example during hormone release, in which a baseline 
release is combined with pulsed, one-shot type release 
within a short time rangeand temporal delivery. A 
pharmaceutical dosage form such as a capsule capable of 
delivering therapeutic agents into the body in a time-
controlled or position-controlled pulsatile release fashion, 
is composed of a multitude of multicoated particulates 
(beads, pellets,granules, etc.) made of one or more 
populations of beads. On which cases or circumstance 
pulsatile drug delivery is used they are listed below. 
1) Chronopharmacotherapy of diseases which shows 
circadian rhythms in their pathophysiology.  
2) Avoiding the first pass metabolism e.g. protein and 
peptides2 
3) For which the tolerance is rapidly exists,  
4) For targetting specific site in intestine e.g. colon,  
5) For time programmed administration of hormone and 
drugs,  
6) For drugs having the short half life  and their 
mechanism. 
Drugs which exhibit tolerance that drugs not be delivered 
at a constant rate, since the drug effect decreases with 
time at constant drug level. The drug toxicity increases 
with time. In such cases it is preferable for dosage form 
which will provide desired concentration of drug at 
particular time point only. Now the concept of  
chronopharmaceutics  has emerged, where is research  
devoted to the design and evaluation of drug delivery 
systems that release a therapeutic agent at a rhythm that 
ideally matches the biological requirement of a given 
disease therapy. “Chronopharmaceutics” consist of two 
words chronobiology and pharmaceutics. Chronobiology 
is the study of biological rhythms. There are three types 
of mechanical rhythms in our body.  
They are: 
1. Circadia 
 2. Ultradian 
3. Infradian.  
Circadian This word comes from Latin word “circa” 
means about and “dies” means day Ultrdian Oscillation of 
shorter duration is called as ultradian (more than one 
cycle per 24 h ) Infradian Oscillations that are longer than 
24 h (less than one cycle per day). Diseases where a 
constant levels of drug the are not preferred, but needs a 
pulse of therapeutic concentration in a periodic manner 
acts as a push for development of “Pulsatile Drug 
Delivery Systems”4. 
MERITS
5
: 
Predictable, reproducible and short gastric residence time 
Less inter- and intra-subject variability 
Improve bioavailability 
Limited risk of local irritation 
No risk of dose dumping 
Flexibility in design 
Improve stability 
ABSTRACT 
Pulsatile drug delivery is a advanced  drug delivery system in pharmaceutical field . Pulsatile system is one of the modified 
release dosage form system  and gaining a lot of interest as it is increasing patient compliance by means of providing time- 
and site-specific drug delivery system. Pulsed or pulsatile drug release is defined as the rapid and transient release of a 
certain amount of drug molecules within a short time-period immediately after a predetermined off-release period.  In various 
diseases in which we can recomend the pulsatile drug delivery system such as  duodenal ulcer, cardiovascular diseases, 
arthritis, asthma, diabetes, neurological disorder, cancer, hypertension and hypercholesterolemia. This article summarize the 
various methodologies,  evaluation parameters and compile the recent literatures with special focus on the different types and 
approaches involved in the development of the formulation 
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DEMERITS
5
: 
Lack of manufacturing reproducibility and efficacy 
Large number of process variables 
Batch manufacturing process  
Higher cost of production 
Trained/skilled personal needed for manufacturing 
NECESSITIES OF PULSATILE DDS
6
: 
1. First pass metabolism: 
Some drugs, such as beta blockers, and salicylamide, 
undergo extensive first pass metabolism and require fast 
drug input to saturatemetabolizing enzymes in order to 
minimize pre-systemic metabolism. Thus, a 
constant/sustained oral method of delivery would result in 
reduced oral bioavailability. 
2. Biological tolerance: 
Drug plasma profiles are explain by a decline in the 
pharmacotherapeutic effect of the drug, e.g., biological 
tolerance of transdermal nitroglycerin, salbutamol 
sulphate. 
3. Special chronopharmacological needs: 
Circadian rhythms in certain physiological functions are 
well established. It has been recognized that many 
symptoms and onset of disease occur during specific time 
periods of the 24 hour day, e.g., asthma and angina 
pectoris attacks are most frequently in the morning hours. 
4. Local therapeutic need: 
For the treatment of local disorders such as inflammatory 
disease, the delivery of compounds to the site of 
inflammation with no loss due to absorption in the small 
intestine is highly desirable to achieve the therapeutic 
effect and to minimize side effects. 
5. Gastric irritation or drug instability in gastric fluid:  
Protection for those drugs  are essential which are 
effected by gastric acidic environment and  undergo 
degradation in gastric acidic medium (eg, peptide drugs), 
irritate the gastric mucosa (NSAIDS) or induce nausea 
and vomiting. 
Classification of pulsatile drug delivery systems
6, 7
 
Pulsatile drug delivery systems (PDDS) is classified in 
two systems one is site-specific and other is time-
controlled systems. Drug release from site-specific 
systems depends on the environment in the gastro 
intestinal track, e.g., on pH, presence of enzymes etc. In 
contrast, time-controlled DDS are independent of the 
biological environment. The drug release is controlled 
only by the system. Time-controlled pulsatile delivery has 
been achieved mainly with drug containing cores, which 
are covered with release-controlling layers Figure 1.
 
 
                                            Figure 1: Classification of Pulsatile drug delivery system
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1. TIME-CONTROLLED  SYSTEM 
Time-dependent dosage forms are those dosage forms 
which are formulated to release their drug load after a 
predetermined lag time. To achieve a drug release that is 
independent of the environment (e.g. pH, enzymatic 
activity, intestinal motility) and/or other stimuli, the lag 
time prior to the release of the drug has to be controlled 
primarily by the delivery system8. The release 
mechanisms employed include bulk erosion of polymers 
in which drug release by diffusion is restricted, surface 
erosion of layered devices composed of alternating drug-
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containing and drug-free layers, and osmotically 
controlled rupture 9. 
2. SITE-SPECIFIC SYSTEM 
colon specific dosage forms have been developed 
including pro-drugs, drug embedded in cross-linked 
hydrogel delivery of drugs to the colon can be done to 
achieve many objectives like reduction in dosing 
frequency, to deliver drug to a region that is less hostile 
metabolically efficacy of the drug generally depends upon 
the ability of the drug to reach its target in sufficient 
quantity to maintain therapeutic levels for the desired 
time period . Although, the colon does not inherently 
possess the ideal anatomical and physiological features, it 
is the site of significant absorption. etc10. Other 
commercial benefits can be the ever-greening of already 
existing patents and the ability to promote new claims. In 
the past few years many matrices, coated dosage forms, 
osmotic controlled drug delivery systems and timed 
release systems.  The coated dosage forms are preferred 
because of innovations in the coating technology and 
wide flexibility in the design11. A study on several 
examples for both single and multiple unit gastroretentive 
drug delivery systems has been done by Streubel et al12 
The rationale of drug targeting to the colon which we 
would be focusing on in this review is to delay delivery to 
a time appropriate to treat acute phases of a disease i.e., to 
achieve a chronotherapeutic drug delivery response. 
1. TIME CONTROLE SYSTEM 
A. SINGLE UNIT SYSTEM      
These are sub-classified as capsule-based systems, 
osmotic systems.Delivery systems with soluble or 
erodible membranes and delivery systems with rupturable 
coating. 
(i) TABLET SYSTEM 
Most of the pulsatile drug delivery systems are reservoir 
devices coated with a barrier layer. This barrier erodes or 
dissolves after a specific lag period, and the drug is 
subsequently released rapidly. The lag time depends on 
the thickness of the coating layer. 
(ii) CAPSULAR SYSTEM 
Single unit systems are mostly developed in capsule form. 
The lag time is continued by a plug, which gets pushed 
away by swelling or erosion, and the drug is released as a 
pulse from the insoluble capsule body. e.g.: Pulsincap® 
system In this system a water insoluble body containing 
the drug formulation, system is closed with a swellable 
hydrogel. Plugged (insoluble but permeable &swellable) 
at open end.  For rapid release of water insoluble drug 
effervescent or disintegrating agents are added 13.  
(iii) PULSATILE DELIVERY BY OSMOSIS 
This system consists of a capsule coated with a semi 
permeable membrane. Inside the capsule the drug 
formulation. 
(iv) PULSATILE DELIVERY BY 
SOLUBILISATION (was an insoluble plug consisting 
of osmotically active agent and the drug formulation 14. 
This system shows good invivo and invitro correlation in 
humans and used to deliver methylphenidate to school 
age children for the treatment of Attention Deficit Hyper 
activity Disorder (ADHD), 
e.g.: Port® System Another system is also based on 
expendable orifice that contain capsular system in which 
liquid drug is absorbed on highly porous particles. Drug 
releases through orifice of a semi permeable capsule 
supported by an expending osmotic layer after the barrier 
layer is dissolved 15. The Port® System (Port Systems, 
LLC) consists of a gelatin capsule coated with a semi 
permeable membrane (e.g., cellulose acetate) housing an 
insoluble plug (e.g., lipidic) and an osmotically active 
agent. 
 EROSION OF MEMBRANE 
These systems are based up on a drug reservoir 
surrounded with a soluble or erodible barrier layer that 
dissolves with time and the drug releases at once after the 
lag time. E.g. Time Clock® system. The Time Clock 
system consists of solid dosage form coated with lipid 
barriers such as carnauba wax & beeswax along with 
surfactants like polyoxy ethylene sorbinmono oleate. 
When this system comes in contact with the aqueous 
medium the coat emulsifies or erodes after the lag-time 
depending on the thickness of coat.The lag time of system 
independent of the gastrointestinal motility, PH, enzyme 
& gastric residence 16. 
(v) PULSATILE DELIVERY BY RUPTURE OF 
MEMBRANE 
These systems are based up on a reservoir system coated 
with a rupturable membrane. The outer membrane 
ruptures due to the pressure developed by effervescent 
agents (or) swelling agent 17. Citric acid & sodium 
bicarbonate is incorporated as effervescent mixture in 
tablet core coated with ethyl cellulose, when system 
comes in contact with water it produces carbon dioxide 
gas which exerts pressure & after lag time rupture the 
membrane & rapid release of drug occurs . A reservoir 
system with a semi permeable coating is proposed 
especially with drugs with high first pass effect in order 
to obtain in-vivo drug pattern similar to the 
administration of several immediate release doses 
croscarmellose sodium starch glycollate or low 
substituted hydroxy propyl cellulose were used as 
swelling substances, which resulted in complete film 
rupture followed by rapid drug release. The lag time is 
controlled by composition of outer polymeric membrane. 
B. MULTIPAL UNIT SYSTEMS  
Multiparticulate systems are reservoir type of devices 
with a coating, which either ruptures or changes its 
permeability. Drug is coated over sugar seeds these 
granules may then be packaged in a capsule or 
compressed with additional excipients to form a tablet. 
The active pharmaceutical ingredient may also be blended 
or granulated with polymers before coating to provide an 
additional level of control. However, drug loading in this 
type of system is low due to higher need of excipients. 
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(i) PULSATILE DELIVERY BY RUPTURABLE 
COATING 
Similar to single unit system, the rupturing effect is 
achieved by coating the individual units with effervescent 
(or) swelling agents. Drug deliver was controlled by the 
rupture of the membrane. The timing of release was 
controlled by the thickness of coating and the amount of 
water soluble polymer to achieve the pulsed release. The 
swelling agent includes super disintegrents like 
carboxymethylcellulose, sodium starch glycollate, and L-
hydroxy propyl cellulose. Polymers like polyacrylic acid, 
polyethylene glycol etc. alternatively comprising of a 
mixture of tartaric acid & sodium bicarbonate that used as 
effervescent agent 18. The lag time is controlled by 
composition of outer polymeric membrane. 
METHODOLOGIES FOR PULSATILE DRUG 
DELIVERY SYSTEM 
Methodologies for the pulsatile drug delivery system can 
be broadly classified into three classes: 
1. Time controlled 
2. Stimuli induced 
3. Externally regulated 
4. Multipaticulate system 
1. TIME CONTROLLED PULSATILE RELEASE 
SYSTEM   
In time controlled drug delivery systems pulsatile release 
is obtained after a specific time interval in order to mimic 
the circadian rhythm. Such type of pulsatile drug delivery 
system contains two Components: one is of immediate 
release type and other one is a pulsed release type. 
Various methodologies that can be used for time 
controlledpulsatile release systems are discussed in 
following section. 
(i) Delivery systems with rupturable coating layer 
These systems consist of an outer release controlling 
water insoluble but permeable coating subject to 
mechanically induced rupture phenomenon. Recently 
different systems based on hard gelatin capsules, all 
coated by inner swellable and outer rutpurable layer. The 
film rupture may be attained by including swelling, 
osmotic oreffervescent additives in the reservoir. By 
optimizing the system, drug release can be obtained at 
specific time interval.  
 
Figure 2:  Schematic Diagram of delivery System with 
rupturable coating drug
7
 
(ii) Delivery systems provided with erodible coating 
layers 
In such systems the drug release is controlled by the 
dissolution or erosion of the outer coat which is applied 
on the core containing drug. Time dependent release of 
the active ingredient can be obtained by optimizing the 
thickness of the outer coat. Sangalliet al. developed an 
oral dosage form devised to release drugs following a 
programmed time period after administration based on 
this concept.  
(iii) Capsule shaped system provided with release 
controlling plug 
These systems contain release controlling plug between 
immediate release compartment and pulsed release 
compartment. On contact with aqueous fluids, the cap 
rapidly dissolves thereby releasing the immediate release 
component followed by pulsed release component. The 
lag time is provided by the plug which is inserted in to the 
body. In an approach used by Jimoh et al, pulsatile 
release was achieved by generation of hydrostatic 
pressure inside the capsule.  
3. STIMULI INDUCED PULSATILE SYSTEMS  
In these systems there is release of the drug after 
stimulation by any biological factor like temperature, or 
any other chemical stimuli. These systems are further 
classified in to temperature induced systems and chemical 
stimuli induced system, on the basis of stimulus. 
(i) Temparature induced systems 
Thermo-responsive hydrogel systems have been 
developed for pulsatile release. In these systems 
thepolymer undergoes swelling or deswelling phase in 
response to the temperature which modulate drug release 
in swollen state18. Y.H. Bae et al developed indomethacin 
pulsatile release pattern in the temperature ranges 
between 200C and 300C by using reversible swelling 
properties of copolymers of N-isopropylacrylamide and 
butyrylacrylamide. Kataokaet al developed the thermo 
sensitive polymeric micelles as drug carrier to treat the 
cancer.  
(ii) Chemical stimuli induced pulsatile systems  
(a) Glucose-responsive insulin release devices 
In case of diabetes mellitus there is rhythmic increase in 
the levels of glucose in the body requiring injection of the 
insulin at proper time. Several systems have been 
developed which are able to respond to changes in 
glucose concentration. One such system includes pH 
sensitive hydrogel containing glucose oxidase 
immobilized in the hydrogel. When glucose concentration 
in the blood increases glucose oxidase converts glucose 
into gluconic acid which changes the pH of the system. 
This pH change induces swelling of the polymer which 
results in insulin release. Insulin by virtue of its action 
reduces blood glucose level and consequently gluconic 
acid level also gets decreased and system turns to the 
deswelling mode thereby decreasing the insulin release. 
Examples of the pH sensitive polymers includes 
N,Ndimethylaminoethylmethacrylate. 
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Figure 3:  Schematic diagram of drug delivery with release controlling plug
5
 
 (b) Inflammation-induced pulsatile release 
On receiving any physical or chemical stress, such as 
injury, fracture etc., inflammation take place at the 
injured sites.During inflammation, hydroxyl radicals are 
produced from these inflammation-responsive cells. Yui 
and co-workers focused on the inflammatory 
inducedhydroxyl radicals and designed drug delivery 
systems, which responded to the hydroxyl radicalsand 
degraded in a limited manner. 
(c) Drug releasefrom intelligent gels responding to 
antibody concentration 
There are numerous kinds of bioactive compounds which 
exist in the body. Recently, novel gels were developed 
which responded to the change in concentration of 
bioactive compounds to alter their swelling/deswelling 
characteristics. Special attention was given to antigen-
antibody complex formation as the cross-linking units in 
the gel, since such interaction is very specific.  
(d) PH sensitive drug delivery system 
Such type of pulsatile drug delivery system contains two 
components one is of immediate release type and other 
one is pulsed release which releases the drug in response 
to change in pH. In case of pH dependent system 
advantage has been taken of the fact that there exists 
different pH environment at different parts of the 
gastrointestinal tract. By selecting the pH dependent 
polymers drug release at specific location can be 
obtained. An example of pH dependent polymers includes 
cellulose acetate phthalate,polyacrylates, and 
sodiumcarboxymethylcellulose. Externally regulated 
systems for releasing the drug in a pulsatile manner, 
another way can be the externally regulated systems in 
which drug release is programmed by external stimuli 
likemagnetism, ultrasound, electrical effect and 
irradiation.Magnetically regulated systems contain 
magnetic beads in the implant. On application of the 
magnetic field, drug release occurs because of magnetic 
beads.    
(iii) Magnetic stimuli-induced pulsatile release  
Use of an oscillating magnetic held to regulate the rates 
of drug delivery from a polymer matrix was one of the 
first methodologies investigated to achieve an externally 
controlled drug delivery system. Magnetic steel beads 
were engrafted in an ethylene and vinyl acetate (EVAc) 
copolymermatrix that was loaded with bovine serum 
albumin as a model drug. Edelman and coworkersproved 
increased rates of drug release in the presence of an 
oscillating magnetic field.The beads oscillate within the 
matrix on exposure to the magnetic field, alternatively 
creatingcompressive and tensile forces. This in turn acts 
as a pump to push more amount of the activesolute out of 
the matrix. Co-polymers having higher Young's modulus 
were more resistant tothe induced motion of steel beads, 
and accordingly the magnetic held has less effect onthe 
rate of drug release from these materials. Saslawski and 
co-workers prepared various formulations for in vitro 
magnetically induced pulsatile delivery of insulin based 
on alginate  spheres. In an experiment, ferrite 
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microparticles (1 µm) and insulin powder were dispersed 
in sodium alginate aqueous solution.  
 (iv) Pulsatile system based on osmosis 
The delivery of agents from osmotic systems is based on 
expandable orifice technology was developed. This 
system is in the form of capsule with an orifice.The 
capsule wall is constructed of an elastic material (e.g., 
styrene-butadiene copolymer), and stretches under a 
pressure differential caused by the pressure rise inside the 
capsule due to osmotic infusion of moisture from the 
body. When this elastic wall is stretched, because of 
pressure differential across the wall, exceeding a 
threshold, the orifice expands sufficiently to allow the 
release of the drug at a physiologically required rate. 
However, when the elastic wall is relaxed, the flow rate 
of the drug through the orifice is substantially zero. 
(v) Thermoresponsive hydrogel systems: 
Thermo-responsive hydrogel systems employ hydrogels 
which undergo reversible volume changes in response to 
changes in temperature. These gels shrink at a transition 
temperature that is referred to the lower critical solution 
temperature (LCST) of the linear polymer. Thermo-
sensitive hydrosensitive hydrogels have a certain 
chemical attraction for water, and therefore they absorb 
water and swell at temperatures below the transition 
temperature whereas they shrink or deswell at 
temperatures above the transition temperature by 
expelling water. Thermally responsive hydrogels and 
membranes have been extensively exploited as platforms 
for the pulsatile drug delivery20. 
(vi) Thermoresponsive polymeric micelle systems: 
In this type, the gel system tightly stores targeted drug in 
the micelles and rapidly releases controlled amount of the 
drug by switching on–off of external stimuli such as 
temperature or infrared laser beam. Jianxiang Zhang, et al 
synthesized thermally responsive amphiphilicpoly(N 
isopropylacrylamide) (PNIPAm)-graftedpolyphosphazene 
(PNIPAm-g- PPP) by stepwise cosubstitution of chlorine 
atoms on polymer backbones with amino-terminated 
NIPAm oligomers and ethyl glycinate(GlyEt). Diflunisal 
(DIF)-loaded micelles were prepared by dialysis method. 
In vitro release test at various temperatures was also 
performed to study the effect of temperature on the drug 
release profiles. 
(vii) EnzymaticaIIy-activated Liposome: 
Drug loaded liposomes was incorporated into 
microcapsules of alginate hydrogels. Liposomes inside 
the microcapsules were coated with phospholipase A2 to 
achieve a pulsatile release of drug molecules. 
Phospholipase A2 was shown to accumulate at the 
water/liposome interfaces and remove an acyl group from 
the phospholipids in the liposome. Destabilised liposomes 
release their drug molecules, thus allowing drug release to 
be regulated by the rate determining microcapsule 
membrane21,22. 
3. Externally regulated pulsatile release system: 
This system is not self-operated, but instead requires 
externally generated environmental changes to initiate 
drug delivery. These can include magnetic fields, 
ultrasound, electric field, light, and mechanical force. 
(i) Magnetic induces release:  
Magnetic carriers receive their magnetic response to a 
magnetic field from incorporated materials such as 
magnetite, iron, nickel, cobalt etc. Magnetic-sensitive 
behavior  for controlled release of drug was studied by 
Tingyu Liu, et al. An intelligent magnetic hydrogel 
(ferrogel) was fabricated by mixing poly (vinyl alcohol) 
(PVA) hydrogels and Fe3O4 magnetic particles through 
freezing-thawing Cycles23. Although the external direct 
current magnetic field was applied to the ferrogel, the 
drug got accumulated around the ferrogel, but the 
accumulated drug spurt to the environment instantly when 
the magnetic fields instantly switched “off”. Furthermore, 
rapid slow drug release can be tunable while the magnetic 
field was switched from “off” to “on” mode. The drug 
release behavior from the ferrogel is strongly dominated 
by the particle size of Fe3O4 under a given magnetic 
field24.Tingyu Liu, et al developed the magnetic 
hydrogels which was successfully fabricated by 
chemically crosslinking of gelatin hydrogels and Fe3O4 
nanoparticles (ca. 40–60 nm) through genipin (GP) as 
cross-linking agent.25 
(ii) Ultrasound induces release: 
Ultrasound is mostly used as an enhancer for the 
improvement of drug permeation through biological 
barriers, such as skin. The interactions of ultrasound with 
biological tissues is divided into two broad categories: 
thermal and nonthermal effects. Thermal effects are 
associated with the absorption of acoustic energy by the 
fluids or tissues26. Non-thermal bio-effects are generally 
associated with oscillating orcavitating bubbles, but also 
include noncavitation effects such as radiation pressure, 
radiation torque, and acoustic streaming. 
 (iii) Electric field induces release: 
Electrically responsive delivery systems are prepared by 
polyelectrolytes (polymers which contain relatively high 
concentration of ionisable groups along the backbone 
chain) and are thus, pH-responsive as well as electro-
responsive. Under the influence of electric field, electro-
responsive hydrogels generally bend, depending on the 
shape of the gel which lies parallel to the electrodes 
whereas deswelling occurs when the hydrogel lies 
perpendicular to the electrodes. 
(iv)  Light induces release: 
Light-sensitive hydrogels have potential applications in 
developing optical switches, display units, and opthalmic 
drug delivery devices27. The interaction between light and 
material can be used to modulate drug delivery. When 
hydrogel absorb the light and convert it to heat, raising 
the temperature of composite hydrogel above its LCST41, 
hydrogel collapses and result in an increased rate of 
release of soluble drug held within the matrix. 
4. Multipaticulate system: 
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Recent trends indicate that multiparticulate drug delivery 
systems are especially suitable for achieving controlled or 
delayed release oral formulations with low risk of dose 
dumping, flexibility of blending to attain different release 
patterns as well as reproducible and short gastric 
residence time. Such systems are reservoir type with 
either rupturable or altered permeability coating and 
generally housed in capsular body. The purpose of 
designing multiparticulate dosage form is to develop a 
reliable formulation that has all the advantages of a single 
unit formulation and yet devoid of the danger of alteration 
in drug release profile and formulation behaviourdueto 
unit to unit to unit variation28.  
 
Figure 4: Hypothetical design of a multiparticulate 
pulsatile system
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Andrei Dashevsky, et al. developed a pulsatile 
multiparticulate drug delivery system (DDS), coated with 
aqueous dispersion of Aquacoat® ECD. A rupturable 
pulsatile drug delivery system consists of (i) a drug core; 
(ii) a swelling layer, comprising a superdisintegrant and a 
binder; and (iii) an insoluble, water-permeable polymeric 
coating29. Upon water ingress, the swellable layer 
expands, resulting in the rupturing of outer membrane 
with subsequent rapid drug release. Regarding the cores, 
the lag time was shorter; theophylline was layered on 
sugar cores compared with cores consisting of 
theophylline. Regarding swelling layer, the release after 
lag time was fast and complete. Drug release was 
achieved after the lag time, when low-substituted 
hydroxypropyl cellulose (L-HPC) and sodium starch 
glycolate(Explotab®) were used as swelling agents. Outer 
membrane, formed using aqueous dispersion Aquacoat® 
ECD was brittle and ruptured sufficiently to ensure fast 
drug release, compared to ethylcellulose membrane 
formed using organic solution. The addition of talc led to 
increase brittleness of membrane and was very 
advantageous. Drug release starts only after rupturing of 
outer membrane23. 
EVALUATION OF PULSATILE DRUG DELIVEY 
SYSTEM 
In vitro method 
Dissolution studies 
Dissolution studies were carried out by using USB Paddle 
dissolution test apparatus. Capsule were tried to paddle 
with a cotton thread so that the capsule should be 
immersed completely in dissolution media but not float. 
In order to stimulate the PH changes along the GIT tract, 
three dissolution media with PH 1.2, 7.4, and 6.8 were 
sequentially used, reffered to as sequential PH change 
method when performing experiments, the PH 1.2 
Medium was first used for 2h (since the average gastric 
emptying time is 2h), then removed and the first PH 7.4 
phosphate buffer saline (PBS) was added. After 3h 
(average small intestinal transit time is 3h), the medium 
was removed and fresh PH 6.8 Dissolution medium was 
added for subsequent hours. Nine hundred milliliters of 
the dissolution medium was used at each time. Rotation 
speed was 100 rpm and temperature was maintained. 
Capsule were tried to paddle with cotton thread in each 
dissolution vessel to prevent floating. Five milliliters of 
dissolution media was replaced. The withdrawn sample 
were analyzed at 296nm, by UV absorption spectroscopy 
and the cumulative percentage release was calculated 
over the sampling times26. 
Table 1: In-vivo method 
S.No. Drug (polymer) Method Ref 
1. 
 
Verapamil hydrochloride, 
hydroxypropyl methylcellulose 
(HPMC, Methocel® E5, E15, E50), 
ethylcellulose (EC, Ethocel® 45P) 
Gamma scintigraphy: six healthy males administrated two capsules 
eachvolunteer, 4 h after dinner and then remained supine 8 h 
following the dose, with200 ml of water containing 99mTc-DTPA. 
The images taken at 30-min intervalsby a gamma camera the 
gastrointestinal transit of the dosage forms 
 
 
28 
2. Dofetilide (PulsincapTM), 
EC, polyethylene glycol 
 
An open, four-way crossover study in which male fasted subjects. 
In additionto the three doses of dofetilide administered to eleven 
subjects gamma camerafitted with a medium energy collimator, 
scintigraphic images of 30 s duration.Each imaging interval a blood 
sample (5 ml) was taken from a forearm vein. 
 
 
29 
3. Metoprolol tartrate, 
impermeable capsule 
 
Two male and two female mongrel dogs administered hard gelatin 
capsulespacked with two doses (50 mg + 120 mg) were studies 
carried out on over nightfasting condition. Plasma samples were 
taken by repeated.  
 
30 
4. Acetaminophen, Methocel® E5, 
Aquacoat®, ECD 
 
Five healthy volunteers administered pellets with with 250 ml water 
after a 10h overnight fasting. Saliva collected at predetermined time 
intervals were keptfrozen at 60˚C until analytical assessment. 
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APPLICATION OF PULSATILE DRUG DELIVERY 
SYSTEM 
Thorough understanding of the disease physiology is 
required before designing the pulsatile drug delivery 
system. Diseases where rhythmic circadian organization 
of the body plays an important role, pharmacokinetics 
and/or pharmacodynamics of the drugs is not constant 
within 24 h. Table enumerates various diseases showing 
such a chronological behavior. Asthma is one such 
disease where pulsatile drug delivery system can be 
useful. Circadian changes are seen in normal lung 
function, which reaches a low point in the early morning 
hours. In case of cardiovascular diseases, several 
functions (e.g. BP, heart rate, stroke volume, cardiac 
output, blood flow) of the cardiovascular system are 
subject to circadian rhythms. For instance, capillary 
resistance and vascular reactivity are higher in the 
morning and decrease later in the day28,30. 
 
Table 2: Diseases requiring pulsatile drug delivery 
Disease Chronological behavior Drug used 
Peptic Ulcer Acid secretion is high in the afternoon and at night H2 blockers 
Asthma Precipitation of attacks during or at early morning hour β2 agonist, Antihistaminics 
Cardiovascular diseases BP is at its lowest during the steep cycle and rises 
steeply during the early morning awakening period 
Nitroglycerin, Calcium Channel 
blocker, ACE inhibitors etc 
Arthritis Pain in the morning and more pain at night NSAIDs, Glucocorticoids 
Diabetes Mellitus Increase in the blood sugar level after meal Sulfonylurea, Insulin, Biguanide 
Attention deficit syndrome Increase in DOPA level in the afternoon Methylphenidate 
Hypercholesterolemia  Cholesterol synthesis is generally higher during night 
than during day time  
HMG CoA reductase inhibitors 
 
RECENT ADVANCES IN THE PULSATILE DRUG 
DELIVERY 
Nowadays pulsatile drug delivery systems are gaining 
importance in various disease conditions specifically in 
diabetes where dose is required at different time intervals. 
Among these systems, multi-particulate systems (e.g. 
pellets) offer various advantages over single unit which 
include no risk of dose dumping, flexibility of blending 
unitswith different release patterns, as well as short and 
reproducible gastric residence time. Multiparticulate 
systems consists pellets of different release profile which 
can be of any type like time dependent, pH dependent, 
micro flora activated system as discussed in the previous 
sections. Site and time specific oral drug delivery have 
recently been of great interest in pharmaceutical field to 
achieve improved therapeutic efficacy. Gastroretentive 
drug delivery system is an approach to prolong gastric 
residence time, thereby targeting sitespecific drug release 
in upper gastrointestinal (GI) tract. Floating drug delivery 
system (FDDS) and bioadhesive drug delivery are widely 
used techniques for gastro retention. Low density porous 
multiparticulate systems have been used by researchers 
for formulation of FDDS. Sharma and Pawar developed 
multiparticulate floating pulsatile drug delivery system 
using porous calcium silicate and sodium alginate for 
time and site specific drug release of meloxicam. Various 
pulsatile technologies have been developed on the basis 
of methodologies as discussed previously. These includes 
OROS® technology, CODAS® technology, CEFORM® 
technology, DIFFUCAPS® technology, Three-
dimensional printing®, timerx® etc 22, 27, 30. 
CONCLUSIONS 
There is a  need   of new drug  delivery systems that can 
provide increased therapeutic benefits to the patients. 
Pulsatile drug delivery system (PDDS) is one such system  
that delivers the drug at the right time, right place and in 
right amounts, holds good promises of benefit  to the 
patients suffering from chronic problems . Thus, 
designing of proper pulsatile drug delivery will enhances 
the patient compliance, optimum drug delivery to the 
target site and minimizes the undesired effects. PDDS can 
effectively tackle the problems as it is modulated 
according to body's circadian clock giving release of drug 
after a specified time lag. Significant progress has been 
made towards achieving pulsatile drug delivery system 
that can effectively treat diseases with non-constant 
dosing therapy. 
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